the Impact of Metformin Use on Clinical Outcomes in Gouty Patients

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:

• Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.

Locations
Other Locations
Egypt
Tanta Unuversity
RECRUITING
Tanta
Time Frame
Start Date: 2025-04-20
Estimated Completion Date: 2026-11-20
Participants
Target number of participants: 70
Treatments
Active_comparator: Control group
this group will receive placebo in addition to the traditional lines of treatment of gout.
Active_comparator: Metformin group
This group will receive metformin (1000mg/day) in addition to the traditional lines of treatment of gout.
Sponsors
Leads: Mostafa Bahaa

This content was sourced from clinicaltrials.gov